Haley Q. Marcarian, Anutr Sivakoses, Anika M. Arias, Olivia C. Ihedioha, Benjamin R. Lee, Maria C. Bishop, Alfred L.M. Bothwell
{"title":"肾癌细胞通过逆行吞噬和水平基因转移获得免疫表面蛋白","authors":"Haley Q. Marcarian, Anutr Sivakoses, Anika M. Arias, Olivia C. Ihedioha, Benjamin R. Lee, Maria C. Bishop, Alfred L.M. Bothwell","doi":"10.1101/2024.08.07.607036","DOIUrl":null,"url":null,"abstract":"Trogocytosis is an underappreciated phenomenon that shapes the immune microenvironment surrounding many types of solid tumors. The consequences of membrane-bound proteins being deposited from a donor immune cell to a recipient cancer cell via trogocytosis are still unclear. Here, we report that human clear cell renal carcinoma tumors stably express the lymphoid markers CD45, CD56, CD14, and CD16. Flow cytometry performed on fresh kidney tumors revealed consistent CD45 expression on tumor cells, as well as varying levels of the other markers mentioned previously. These results were consistent with our immunofluorescent analysis, which also revealed colocalization of lymphoid markers with carbonic anhydrase 9 (CAIX), a standard kidney tumor marker. RNA analysis showed a significant upregulation of genes typically associated with immune cells in tumor cells following trogocytosis. Finally, we show evidence of chromosomal DNA being transferred from immune cells to tumor cells during trogocytosis. This horizontal gene transfer has transcriptional consequences in the recipient tumor cell, resulting in a fusion phenotype that expressed both immune and cancer specific proteins. This work demonstrates a novel mechanism by which tumor cell protein expression is altered through the acquisition of surface membrane fragments and genomic DNA from infiltrating lymphocytes. These results alter the way in which we understand tumor-immune cell interactions and may reveal new insights into the mechanisms by which tumors develop. Additionally, further studies into trogocytosis will help push the field towards the next generation of immunotherapies and biomarkers for treating renal cell carcinoma and other types of cancers. SIGNIFICANCE STATEMENT We have identified trogocytosis as a mechanism by which human clear cell renal carcinoma tumors acquire lymphocyte surface protein expression from tumor infiltrating immune cells. In addition to the transfer of membrane fragments, we have provided evidence to show that genomic DNA is transferred from a normal immune cell to a tumor cell during trogocytosis. This process alters the transcriptome of cancer cells such that they express significantly more mRNA for immune proteins such as the lymphocyte marker CD45 compared to tumor cells that have not undergone trogocytosis. This study provides an in-depth analysis of the interactions between cancer cells and tumor infiltrating lymphocytes, and how these interactions alter the development of human tumors.","PeriodicalId":505198,"journal":{"name":"bioRxiv","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Renal cancer cells acquire immune surface protein through trogocytosis and horizontal gene transfer\",\"authors\":\"Haley Q. Marcarian, Anutr Sivakoses, Anika M. Arias, Olivia C. Ihedioha, Benjamin R. Lee, Maria C. Bishop, Alfred L.M. Bothwell\",\"doi\":\"10.1101/2024.08.07.607036\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Trogocytosis is an underappreciated phenomenon that shapes the immune microenvironment surrounding many types of solid tumors. The consequences of membrane-bound proteins being deposited from a donor immune cell to a recipient cancer cell via trogocytosis are still unclear. Here, we report that human clear cell renal carcinoma tumors stably express the lymphoid markers CD45, CD56, CD14, and CD16. Flow cytometry performed on fresh kidney tumors revealed consistent CD45 expression on tumor cells, as well as varying levels of the other markers mentioned previously. These results were consistent with our immunofluorescent analysis, which also revealed colocalization of lymphoid markers with carbonic anhydrase 9 (CAIX), a standard kidney tumor marker. RNA analysis showed a significant upregulation of genes typically associated with immune cells in tumor cells following trogocytosis. Finally, we show evidence of chromosomal DNA being transferred from immune cells to tumor cells during trogocytosis. This horizontal gene transfer has transcriptional consequences in the recipient tumor cell, resulting in a fusion phenotype that expressed both immune and cancer specific proteins. This work demonstrates a novel mechanism by which tumor cell protein expression is altered through the acquisition of surface membrane fragments and genomic DNA from infiltrating lymphocytes. These results alter the way in which we understand tumor-immune cell interactions and may reveal new insights into the mechanisms by which tumors develop. Additionally, further studies into trogocytosis will help push the field towards the next generation of immunotherapies and biomarkers for treating renal cell carcinoma and other types of cancers. SIGNIFICANCE STATEMENT We have identified trogocytosis as a mechanism by which human clear cell renal carcinoma tumors acquire lymphocyte surface protein expression from tumor infiltrating immune cells. In addition to the transfer of membrane fragments, we have provided evidence to show that genomic DNA is transferred from a normal immune cell to a tumor cell during trogocytosis. This process alters the transcriptome of cancer cells such that they express significantly more mRNA for immune proteins such as the lymphocyte marker CD45 compared to tumor cells that have not undergone trogocytosis. This study provides an in-depth analysis of the interactions between cancer cells and tumor infiltrating lymphocytes, and how these interactions alter the development of human tumors.\",\"PeriodicalId\":505198,\"journal\":{\"name\":\"bioRxiv\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-08-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"bioRxiv\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1101/2024.08.07.607036\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"bioRxiv","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2024.08.07.607036","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
逆行细胞吞噬是一种未得到充分重视的现象,它塑造了许多类型实体瘤周围的免疫微环境。膜结合蛋白从供体免疫细胞通过逆行吞噬作用沉积到受体癌细胞的后果尚不清楚。在此,我们报告了人类透明细胞肾癌肿瘤稳定表达淋巴标记物 CD45、CD56、CD14 和 CD16 的情况。对新鲜肾脏肿瘤进行的流式细胞术显示,肿瘤细胞上的 CD45 表达一致,前面提到的其他标记物也有不同程度的表达。这些结果与我们的免疫荧光分析结果一致,免疫荧光分析还发现淋巴标记物与标准肾肿瘤标记物碳酸酐酶 9(CAIX)共聚焦。RNA 分析表明,在逆行细胞增殖后,肿瘤细胞中与免疫细胞相关的基因明显上调。最后,我们展示了染色体 DNA 在逆行吞噬过程中从免疫细胞转移到肿瘤细胞的证据。这种水平基因转移对受体肿瘤细胞的转录产生了影响,从而形成了同时表达免疫和癌症特异性蛋白的融合表型。这项工作展示了一种新的机制,即通过从浸润淋巴细胞获取表面膜片段和基因组 DNA 来改变肿瘤细胞的蛋白质表达。这些结果改变了我们对肿瘤-免疫细胞相互作用的理解方式,并可能揭示肿瘤发生机制的新见解。此外,对逆行细胞增多症的进一步研究将有助于推动下一代免疫疗法和生物标记物领域的发展,以治疗肾细胞癌和其他类型的癌症。意义声明 我们已经发现,逆行细胞吞噬是人类透明细胞肾癌肿瘤从肿瘤浸润免疫细胞获得淋巴细胞表面蛋白表达的一种机制。除了膜碎片的转移外,我们还提供证据表明,在逆行细胞吞噬过程中,基因组 DNA 会从正常免疫细胞转移到肿瘤细胞。这一过程改变了癌细胞的转录组,使其表达的免疫蛋白(如淋巴细胞标记物 CD45)的 mRNA 明显多于未发生逆行吞噬的肿瘤细胞。这项研究深入分析了癌细胞与肿瘤浸润淋巴细胞之间的相互作用,以及这些相互作用如何改变人类肿瘤的发展。
Renal cancer cells acquire immune surface protein through trogocytosis and horizontal gene transfer
Trogocytosis is an underappreciated phenomenon that shapes the immune microenvironment surrounding many types of solid tumors. The consequences of membrane-bound proteins being deposited from a donor immune cell to a recipient cancer cell via trogocytosis are still unclear. Here, we report that human clear cell renal carcinoma tumors stably express the lymphoid markers CD45, CD56, CD14, and CD16. Flow cytometry performed on fresh kidney tumors revealed consistent CD45 expression on tumor cells, as well as varying levels of the other markers mentioned previously. These results were consistent with our immunofluorescent analysis, which also revealed colocalization of lymphoid markers with carbonic anhydrase 9 (CAIX), a standard kidney tumor marker. RNA analysis showed a significant upregulation of genes typically associated with immune cells in tumor cells following trogocytosis. Finally, we show evidence of chromosomal DNA being transferred from immune cells to tumor cells during trogocytosis. This horizontal gene transfer has transcriptional consequences in the recipient tumor cell, resulting in a fusion phenotype that expressed both immune and cancer specific proteins. This work demonstrates a novel mechanism by which tumor cell protein expression is altered through the acquisition of surface membrane fragments and genomic DNA from infiltrating lymphocytes. These results alter the way in which we understand tumor-immune cell interactions and may reveal new insights into the mechanisms by which tumors develop. Additionally, further studies into trogocytosis will help push the field towards the next generation of immunotherapies and biomarkers for treating renal cell carcinoma and other types of cancers. SIGNIFICANCE STATEMENT We have identified trogocytosis as a mechanism by which human clear cell renal carcinoma tumors acquire lymphocyte surface protein expression from tumor infiltrating immune cells. In addition to the transfer of membrane fragments, we have provided evidence to show that genomic DNA is transferred from a normal immune cell to a tumor cell during trogocytosis. This process alters the transcriptome of cancer cells such that they express significantly more mRNA for immune proteins such as the lymphocyte marker CD45 compared to tumor cells that have not undergone trogocytosis. This study provides an in-depth analysis of the interactions between cancer cells and tumor infiltrating lymphocytes, and how these interactions alter the development of human tumors.